HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Faculty of Pharmaceutical Sciences >
Peer-reviewed Journal Articles, etc >

Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin

Files in This Item:
WoS_94484_Sakamoto.pdf306.75 kBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin
Authors: Sakamoto, Tatsuhiko Browse this author
Saito, Yoshitaka Browse this author
Kobayashi, Masaki Browse this author →KAKEN DB
Yamada, Takehiro Browse this author
Takekuma, Yoh Browse this author →KAKEN DB
Nakai, Masato Browse this author
Ogawa, Koji Browse this author
Iseki, Ken Browse this author →KAKEN DB
Sugawara, Mitsuru Browse this author →KAKEN DB
Keywords: Transcatheter arterial chemoembolization (TACE)
Postembolization syndromes
5-HT3 antagonist
Issue Date: Jul-2020
Publisher: Springer
Journal Title: Supportive care in cancer
Volume: 28
Issue: 7
Start Page: 3251
End Page: 3257
Publisher DOI: 10.1007/s00520-019-05178-1
Abstract: Purpose There are several studies on premedication to prevent postembolization syndromes which occurs after transcatheter arterial chemoembolization (TACE), but the medication to be used is still not established. This study aimed to examine the effect of palonosetron and dexamethasone on the prevention of gastrointestinal symptoms induced by TACE. Methods Patients with hepatocellular carcinoma who were treated with TACE with epirubicin were retrospectively evaluated. The complete response rate of antiemetic drugs and incidence and severity of gastrointestinal symptoms were compared between the antiemetic group (AE group), which includes 51 patients prophylactically administered with palonosetron 0.75 mg and dexamethasone 9.9 mg intravenously before TACE on day 1 and dexamethasone 6.6 mg intravenously on days 2 and 3, and control group with 101 patients without antiemetic premedication. Results Complete response rate in the entire evaluation period was significantly higher in the AE group compared with that in the control group. In the acute phase, the incidence and severity of nausea, vomiting, and anorexia significantly decreased in the AE group, but only anorexia improved in the delay phase. Additionally, postembolization syndromes, such as abdominal pain and fever, were significantly attenuated in the AE group; however, constipation worsened in this group. Conclusions Premedication of palonosetron and dexamethasone significantly prevents the incidence and reduces the severity of gastrointestinal symptoms especially in the acute phase. Further studies will be needed to determine the most recommended 5-HT3 antagonist or dosage of dexamethasone in establishing the optimal antiemetic regimen.
Rights: This is a post-peer-review, pre-copyedit version of an article published in Supportive Care in Cancer. The final authenticated version is available online at:
Type: article (author version)
Appears in Collections:薬学研究院 (Faculty of Pharmaceutical Sciences) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 菅原 満

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University